- Report
- October 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2448EUR$2,789USD£2,130GBP
- Report
- March 2025
- 150 Pages
Global
From €3379EUR$3,850USD£2,940GBP
€4257EUR$4,850USD£3,704GBP
- Report
- August 2018
- 340 Pages
Global
From €3071EUR$3,499USD£2,672GBP
- Report
- June 2024
- 260 Pages
Global
From €6978EUR$7,950USD£6,071GBP
- Report
- May 2024
- 128 Pages
Global
From €3510EUR$3,999USD£3,054GBP
Qutenza is a topical analgesic patch used to treat neuropathic pain. It is a transdermal patch containing 8% capsaicin, a chemical derived from chili peppers. The patch is applied to the skin and works by blocking the transmission of pain signals to the brain. It is approved for use in adults with postherpetic neuralgia, a condition caused by shingles. It is also used to treat other types of neuropathic pain, such as diabetic neuropathy and HIV-related neuropathy.
Qutenza is manufactured by Astellas Pharma Inc. and marketed in the United States by Endo Pharmaceuticals. It is also available in other countries, including Canada, the United Kingdom, and Australia.
Companies in the Qutenza market include Astellas Pharma Inc., Endo Pharmaceuticals, Pfizer, GlaxoSmithKline, and Novartis. Show Less Read more